Description:
<jats:title>Abstract</jats:title><jats:p>Hyaluronan (HA) is a key molecule of the extracellular matrix that is thought to be critically involved in both atherosclerosis and restenosis. Recently, it has been demonstrated that the cyclooxygenase (COX) products, prostacyclin and prostaglandin E<jats:sub>2</jats:sub>, induce HA synthesis <jats:italic>in vitro</jats:italic> by transcriptional up‐regulation of HA‐synthase 2 (HAS2) and HAS1. The relative roles in atherosclerotic and restenotic artery disease of tissue specifically expressed COX‐1 and COX‐2 are still under debate. Thus, the present study aimed to investigate the effect of COX isoform inhibition on HA‐accumulation and regulation of HAS isoform expression in two models of pathologic artery remodelling <jats:italic>in vivo</jats:italic>. Firstly, ApoE‐deficient mice were treated with a prototypic isoform non‐selective inhibitor, indomethacin or with a prototypic COX‐2 selective inhibitor, rofecoxib, for 8 weeks. Aortic HAS mRNA expression and HA‐accumulation in atherosclerotic aortic root lesions were analyzed. Secondly, neointimal hyperplasia was induced by carotid artery ligation in ApoE‐deficient mice on a high fat diet and the effects of the COX inhibitors were determined after 4 weeks of treatment. Intimal HA‐accumulation was markedly reduced in both models by indomethacin and rofecoxib. This coincided with a strong inhibition of HAS1 mRNA expression in both models and with decreased HAS2 mRNA in the aorta of ApoE‐deficient mice. HAS3 was not affected. The repression of HA‐accumulation by both COX‐2 selective and non‐selective COX inhibition implicates COX‐2 in the regulation of HA synthesis <jats:italic>via</jats:italic> stimulation of HAS1 and HAS2 expression <jats:italic>in vivo</jats:italic>. Modulation of vascular HA‐accumulation might play a role in chronic effects of COX inhibitors on the progression of atherosclerosis.</jats:p>